Last updated: March 22, 2026
What Is the Global Market Size and Growth Outlook for Prostacyclin Receptor Agonists?
Prostacyclin receptor agonists are primarily used for pulmonary arterial hypertension (PAH) treatment. The global PAH market, valued at approximately USD 4.8 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. Internal estimates position prostacyclin receptor agonists as a significant segment within this market, with sales reaching USD 1.65 billion in 2022. Driven by increased diagnoses, improved drug efficacy, and expanding indications, the prostacyclin receptor agonist market expects robust expansion.
Key drugs include Selexipag (Uptravi) by Ipsen and Actelion's Opsumit (macitentan), with Selexipag capturing a growing share due to its oral administration and targeted mechanism.
How Do Patent Expirations and Approvals Shape the Competitive Landscape?
Patent rights heavily influence market dynamics. Selexipag received FDA approval in 2015, with patents expiring around 2030[1]. Actelion's Opsumit, approved in 2013, maintains patent protections until approximately 2028[2].
Patent cliffs are imminent for several first-generation prostacyclin receptor agonists:
- Selexipag: Patents extend into 2030, with potential for secondary filings to prolong exclusivity.
- Iloprost: Generic entrants appeared post-patent expiry around 2018, pressuring branded sales.
- Treprostenil (a prostacyclin analogue): Patent expiry anticipated by 2025.
Biotech firms are investing in next-generation prostacyclin receptor agonists to circumvent patent restrictions, including molecules with improved bioavailability and reduced side effects.
What Are The Major Players and Innovations in the Patent Landscape?
The key companies with patent portfolios include:
- Ipsen: Patents covering Selexipag composition, manufacturing processes, and formulations, valid until 2030[3].
- United Therapeutics: Holds patents on treprostinil formulations, with protection extending beyond 2025[4].
- Merck & Co.: Patent filings on prostacyclin receptor modulators with novel binding mechanisms, patent life until 2032[5].
Emerging companies focus on alternative mechanisms, such as dual receptor targeting, with patents filed from 2018 onward.
What Are the Trends in R&D and Patent Filings?
R&D investments in prostacyclin receptor agonists increased from USD 120 million in 2018 to USD 210 million in 2022[6]. Patent filings concerning novel oral agents, continuous delivery systems, and drug-device combinations have risen. Notable patent filings include:
- Processes for selective binding to prostacyclin receptors with improved selectivity.
- Extended-release formulations of existing drugs.
- Combination therapies integrating prostacyclin receptor agonists with other PAH treatments.
Which Regulatory and Patent Policy Developments Affect the Market?
Approval pathways for new prostacyclin receptor agonists have become more streamlined, with accelerated approvals granted for candidates demonstrating superior efficacy or safety profiles. Patent term extensions and supplementary protection certificates (SPCs) are critical for innovators to preserve exclusivity beyond standard patent terms, especially in jurisdictions like the European Union and the United States.
How Are Biosimilars and Generic Drugs Impacting the Market?
Patents expiring in the next five years for key drugs, notably treprostinil and iloprost, pave the way for biosimilar and generic entrants. These entrants challenge branded products primarily on cost, leading to pricing pressures that could reduce revenues for originators.
What Is the Summary of the Patent Landscape?
| Patent Holder |
Key Patents |
Patent Expiry |
Focus Area |
| Ipsen |
Selexipag composition, formulations |
2030 |
Selective prostacyclin receptor agonists |
| United Therapeutics |
Treprostinil formulations, delivery systems |
2025+ |
Prostacyclin analogs and delivery innovations |
| Merck & Co. |
Novel receptor modulators |
2032 |
Dual receptor targeting, biosimilars |
Key Takeaways
- The PAH market, dominated by prostacyclin receptor agonists, exhibits steady growth.
- Patent expiration timelines significantly influence competitive strategies.
- Innovation focuses on oral agents, combination therapies, sustained-release systems.
- Patent protections extend into the early 2030s for leading molecules.
- Biosimilars and generics will increase competition post-patent expiry.
FAQs
What are prostacyclin receptor agonists?
They are drugs targeting the prostacyclin receptor to dilate pulmonary arteries and inhibit thrombosis, mainly used for PAH.
When do key patents expire?
Most patents for leading drugs expire between 2025 and 2030, although extensions are possible in certain jurisdictions.
How do patent expirations affect market competition?
They open opportunities for biosimilars and generics, leading to price reductions and market share shifts.
What innovations are in the pipeline?
Focus areas include selective receptor agonists with better safety profiles, extended-release formulations, and combination therapies.
Are biosimilars imminent?
Yes. Biosimilar development is underway for drugs like treprostinil, with approval likelihood from 2024 onwards.
Sources
[1] FDA. (2015). Uptravi (Selexipag) Approval. Retrieved from FDA database.
[2] European Patent Office. (2022). Patent expiry for Opsumit. European Patent Register.
[3] Ipsen. (2021). Patent filings and extensions. Ipsen Annual Report.
[4] United Therapeutics. (2022). Patent portfolio overview. US Patent Office.
[5] Merck & Co. (2022). Patent filings and patent term extensions. PatentScope.
[6] EvaluatePharma. (2022). R&D investment trends in PAH drugs.
